Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02591888 · ClinicalTrials.gov registry record · Phase 4
Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling
A Phase 4 study, sponsored by TriHealth.
- Terminated
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT02591888 is a Phase 4 study that was terminated before completion, run by TriHealth. The registered enrollment target is 18 participants.
The verdict
NCT02591888, a Phase 4 study, was terminated before completion, sponsored by TriHealth.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
Liposomal bupivacaine or placebo will be administered at the end of a transobturator midurethral sling to determine if there is a difference in a patient's perceived postoperative pain.
Interventions
- DRUG Placebo
- DRUG Liposomal bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02591888
The ClinicalTrials.gov registry entry for NCT02591888 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TriHealth, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02591888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02591888 about?
NCT02591888 is a clinical study titled "Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling". Liposomal bupivacaine or placebo will be administered at the end of a transobturator midurethral sling to determine if there is a difference in a patient's perceived postoperative pain.
What is the current status of trial NCT02591888?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2015-02. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02591888?
The interventions under investigation include: Placebo (DRUG), Liposomal bupivacaine (DRUG).
Who is sponsoring clinical trial NCT02591888?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.